Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, has opened a new technology center for developing dialysis machines at its Schweinfurt, Germany production and development site. About 220 employees from different departments will work together on a project basis in the new 7,500-square-meter (81,000-square-foot) building, in which the company has invested about €22 million.
Due to the pandemic, the opening ceremony was a purely digital event. The online conference included a video tour through the building. In addition, employees presented their future workstations in the technical, laboratory and testing areas, as well as offices, break spaces and conference rooms.
“As much as virtual cooperation from home office works well: In combination with virtual networking, person-to-person interactions on site are irreplaceable, and so I am really looking forward to the cooperation in our new technology center,” said Johann Brede, Project Director of the technology center. “With short and direct access ways and corridors, and an open structure, the entire building is designed for networking and exchanges between different disciplines and teams. This way, we can develop for our patients even better dialysis machines that will also cost less.”
Construction of the five-floor building, which required some 5,700 cubic meters of concrete and 900 tons of steel, took three years. The technology center is built to modern environmental standards and includes, among other features, a “green roof.”
The plant in Schweinfurt, which was established in 1979, is Fresenius Medical Care’s largest development and production facility for dialysis machines and other medical devices. The company now employs more than 1,200 people in the city in northern Bavaria, about 120 kilometers (75 miles) east of Frankfurt. About a third of them work in research and development.
Dialysis machines are among the most important products for treating chronic kidney disease. During treatment, the dialysis machine pumps the patient’s blood through bloodlines, monitors its circulation through the dialyzer, and adds anti-coagulants. Treatments are generally carried out three times weekly, and take between three and six hours each.
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.7 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,092 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 346,553 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.